BACKGROUND & AIMS: Hepatitis C virus (HCV) gains entry into susceptible cells by interacting with cell surface receptor(s). Viral entry is an attractive target for antiviral development because of the highly conserved mechanism. METHODS: HCV culture systems were used to study the effects of phosphorothioate oligonucleotides (PS-ONs), as amphipathic DNA polymers (APs), on HCV infection. The in vivo effects of APs were tested in urokinase plasminogen activator (uPA)/severe combined immunodeficient (SCID) mice engrafted with human hepatocytes. RESULTS: We show the sequence-independent inhibitory effects of APs on HCV infection. APs were shown to potently inhibit HCV infection at submicromolar concentrations. APs exhibited a size-dependent antiviral activity and were equally active against HCV pseudoparticles of various genotypes. Control phosphodiester oligonucleotide (PO-ON) polymer without the amphipathic structure was inactive. APs had no effect on viral replication in the HCV replicon system or binding of HCV to cells but inhibited viral internalization, indicating that the target of inhibition is at the postbinding, cell entry step. In uPA/SCID mice engrafted with human hepatocytes, APs efficiently blocked de novo HCV infection. CONCLUSIONS: Our results demonstrate that APs are a novel class of antiviral compounds that hold promise as a drug to inhibit HCV entry.
BACKGROUND & AIMS:Hepatitis C virus (HCV) gains entry into susceptible cells by interacting with cell surface receptor(s). Viral entry is an attractive target for antiviral development because of the highly conserved mechanism. METHODS:HCV culture systems were used to study the effects of phosphorothioate oligonucleotides (PS-ONs), as amphipathic DNA polymers (APs), on HCV infection. The in vivo effects of APs were tested in urokinase plasminogen activator (uPA)/severe combined immunodeficient (SCID) mice engrafted with human hepatocytes. RESULTS: We show the sequence-independent inhibitory effects of APs on HCV infection. APs were shown to potently inhibit HCV infection at submicromolar concentrations. APs exhibited a size-dependent antiviral activity and were equally active against HCV pseudoparticles of various genotypes. Control phosphodiester oligonucleotide (PO-ON) polymer without the amphipathic structure was inactive. APs had no effect on viral replication in the HCV replicon system or binding of HCV to cells but inhibited viral internalization, indicating that the target of inhibition is at the postbinding, cell entry step. In uPA/SCIDmice engrafted with human hepatocytes, APs efficiently blocked de novo HCV infection. CONCLUSIONS: Our results demonstrate that APs are a novel class of antiviral compounds that hold promise as a drug to inhibit HCV entry.
Authors: Didier Samuel; Thierry Bizollon; Cyrille Feray; Bruno Roche; Si Nafa Si Ahmed; Catherine Lemonnier; Marielle Cohard; Michel Reynes; Michelle Chevallier; Christian Ducerf; Jacques Baulieux; Michael Geffner; Janice K Albrecht; Henri Bismuth; Christian Trepo Journal: Gastroenterology Date: 2003-03 Impact factor: 22.682
Authors: Heidi Barth; Christiane Schafer; Mohammed I Adah; Fuming Zhang; Robert J Linhardt; Hidenao Toyoda; Akiko Kinoshita-Toyoda; Toshihiko Toida; Toin H Van Kuppevelt; Erik Depla; Fritz Von Weizsacker; Hubert E Blum; Thomas F Baumert Journal: J Biol Chem Date: 2003-07-16 Impact factor: 5.157
Authors: Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating Journal: Proc Natl Acad Sci U S A Date: 2003-05-21 Impact factor: 11.205
Authors: Miriam Triyatni; Bertrand Saunier; Padma Maruvada; Anthony R Davis; Luca Ulianich; Theo Heller; Arvind Patel; Leonard D Kohn; T Jake Liang Journal: J Virol Date: 2002-09 Impact factor: 5.103
Authors: Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant Journal: Antiviral Res Date: 2017-11-08 Impact factor: 5.970
Authors: Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant Journal: Virol J Date: 2009-12-02 Impact factor: 4.099